Biogen (BIIB)
(Delayed Data from NSDQ)
$154.27 USD
+4.66 (3.11%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $152.68 -1.59 (-1.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Biogen Inc. has a PEG ratio of 1.12 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.58.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIIB 154.27 +4.66(3.11%)
Will BIIB be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for BIIB
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
Other News for BIIB
Is BIIB showing upside potential? 20 Day Moving Average Support shows up after advancing 3.11%
Biogen’s Strategic Advancements and Diversification Drive Buy Rating
Biogen (BIIB) Rating Maintained as RBC Capital Lowers Price Target | BIIB Stock News
Biogen’s Market Challenges and Opportunities: Hold Rating Amid Competitive Pressures and Strategic Uncertainties
Is BIIB gaining bullish strength? Crossed Above 20 Day Moving Average shows up after gaining 1.18%